CTOs on the Move

Zimek Technologies

www.zimek.com

 
Zimek Technologies is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.zimek.com
  • 9328 Florida Palm Dr
    Tampa, FL USA 33619
  • Phone: 800.719.4635

Executives

Name Title Contact Details

Similar Companies

Laboratory Specialists

Laboratory Specialists is a Toledo, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alcon

Alcon, A Division of Novartis, is the global leader in eye care. Our mission is to discover new ways to enhance sight and improve people`s lives. We were founded in 1945 as a small ophthalmic shop in Fort Worth, Texas. Over the past 70 years, we have become the world`s leading eye care company through a combination of innovative research and development, strategic acquisitions, and partnerships with renowned third-party organizations. Today, we proudly reach more than 90 percent of the globe – operating in more than 75 countries, serving 180 markets and employing more than 18,000 people.

Lasergen

Lasergen is an emerging biotechnology company focused on commercializing novel technologies for DNA sequencing. Our expertise in nucleotide chemistry and next-generation sequencing has led to a number of key discoveries resulting in both game-changing sequencing chemistry (Lightning Terminators™) and a more accurate sequencing platform. While focusing on the development of current cutting-edge technology, our continued drive for innovation and extensive sequencing knowledge allows us to rapidly evolve and keep pace with fast-changing advances in the sequencing industry.

CoActiv Medical Business Solutions

CoActiv Medical Business Solutions is a Ridgefield, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

JenaValve

JenaValve Technology, Inc., based in Irvine, California and Munich, Germany develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease. The Company’s transapical TAVI system is CE marked and currently marketed in Europe and other markets worldwide and its new transfemoral TAVI system is currently undergoing clinical evaluation in Europe with a view toward achieving CE Mark in 2015. JenaValve is backed by world-class U.S., European and Asian investors, including Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.